Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 11/20 | 0.41 |
| ▸ | CTSS | P25774 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7455263 | 0.87 | CA1 (0.45) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL5447582 | 0.85 | CA1 (0.47) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL5433610 | 0.83 | CA1 (0.46) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL5873409 | 0.83 | CA1 (0.46) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL16232686 | 0.81 | CA1 (0.46) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL12915836 | 0.81 | CA1 (0.46) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL14923588 | 0.81 | CA1 (0.46) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL768534 | 0.79 | CA1 (0.47) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL6632972 | 0.79 | CA1 (0.47) | CA1CA2CA7KMT2ACYP2D6 | |
| SCHEMBL2386106 | 0.79 | CA1 (0.47) | CA1CA2CA7KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | CA1 4390/4885CA2 3251/4885CA7 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.